Gene-based medicines

Transforming the lives of patients                            with serious diseases

Corporate Presentation

OVERVIEW

Stock Information


May 8, 2019 1:24 PM EDT
Copyright Nasdaq. Minimum 15 minutes delayed.

Press Releases

May 01, 2019

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Apr 29, 2019

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results

Apr 16, 2019

CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia

Apr 01, 2019

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

View All

Upcoming Events & Recent Presentations

May 21, 2019 at 11:00 AM EDT
UBS Global Healthcare Conference
May 15, 2019 at 1:00 PM PDT
Bank of America Merrill Lynch 2019 Health
May 2019
CRISPR Therapeutics Corporate Presentation
May 2019
2019 ASGCT Annual Meeting Poster: CRISPR/Cas9 Gene Editing to Produce Multiple Allogeneic CAR-T Cell Candidates Showing Consistently High Potency, Durability, Lack of Alloreactivity, and Ability to Overcome Immune Suppression
Apr 2019
2019 American Association for Cancer Research (AACR) Annual Meeting Poster: Targeting multiple solid tumor types with anti-CD70 allogeneic CAR-T cells
Apr 2019
2019 American Association for Cancer Research (AACR) Annual Meeting Poster: Allogeneic CRISPR/Cas9 Gene-edited CAR-T Cells Targeting CD33 Show Potent Preclinical Activity Against AML Cells
Dec 2018
2018 Annual Meeting of The American Society of Hematology (ASH) Poster: Preclinical Development of CTX120, an Allogeneic CAR-T Cell Product Candidate Targeting BCMA
Nov 2018
2018 Annual Meeting of The Society for Immunotherapy of Cancer (SITC) Poster: CRISPR/Cas9 Enables the Efficient Production of Allogeneic CAR-T Cells Engineered to Contain Multiple Genome Edits to Enhance Therapeutic T Cell Function
May 2018
2018 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting Poster: Allogeneic CAR-T Cells with Multiple Therapeutically Favorable Edits Can Be Created Efficiently Using CRISPR/Cas9
Apr 2018
2018 American Association for Cancer Research (AACR) Annual Meeting Poster: Allogeneic CRISPR Engineered Anti-CD70 CAR-T Cells Demonstrate Potent Preclinical Activity Against Both Solid and Hematological Cancer Cells
Apr 2018
2018 American Association for Cancer Research (AACR) Annual Meeting Poster: Allogeneic Chimeric Antigen Receptor T Cells Targeting B Cell Maturation Antigen

View All